Ishikawa Takuya, Sakai Hiroyuki, Itaya Tokutaro, Hirotsugu Suwanai, Shikuma Jumpei, Miwa Takashi, Suzuki Ryo, Odawara Masato
Department of Diabetes, Metabolism and Endocrinology, Tokyo Medical University, 6-7-1 Nishishinjuku Shinjuku-ku, Tokyo, 160-0023, Japan.
Thyroid Res. 2021 Jul 10;14(1):17. doi: 10.1186/s13044-021-00108-y.
Anti-streptavidin antibodies are causal determinants of analytical interference during Thyroid function tests, and numerous reports have detailed such interference, with anti-streptavidin antibodies attracting attention.
We conducted a straightforward investigation of interference due to anti-streptavidin antibodies, with a case of a 60-year-old Japanese man who consulted our department for inconsistencies between his clinical course and Thyroid function tests. Experiments were conducted using Cobas8000 e602, which employs assay procedures with pre-wash to evaluate FT4 and FT3 levels.
To our knowledge, this is the first published report to clearly investigate such interferences using a combination of polyethylene glycol precipitation, heterophilic blocking tube precipitation, streptavidin-coated magnetic particle precipitation, and different instruments with or without pre-wash. Clinicians should consider that interferences caused by anti-streptavidin antibodies could lead to a misdiagnosis of thyrotoxicosis. Moreover, discussions between laboratory specialists, clinicians, and manufacturers are required to identify interferences and avoid unnecessary examinations and inappropriate treatment.
抗链霉抗生物素蛋白抗体是甲状腺功能测试中分析干扰的因果决定因素，许多报告详细描述了这种干扰，抗链霉抗生物素蛋白抗体因此受到关注。
我们对一名60岁日本男性患者进行了一项关于抗链霉抗生物素蛋白抗体引起干扰的直接调查，该患者因临床病程与甲状腺功能测试结果不一致前来我科就诊。实验使用了Cobas8000 e602，该仪器采用预洗测定程序来评估FT4和FT3水平。
据我们所知，这是第一份发表的报告，明确使用聚乙二醇沉淀、嗜异性阻断管沉淀、链霉抗生物素蛋白包被磁颗粒沉淀以及有无预洗的不同仪器组合来研究此类干扰。临床医生应考虑到抗链霉抗生物素蛋白抗体引起的干扰可能导致甲状腺毒症的误诊。此外，实验室专家、临床医生和制造商之间需要进行讨论，以识别干扰并避免不必要的检查和不适当的治疗。
